A mechanism study of tripartite motif 10 modulating septic cardiomyopathy DOI Open Access
Zhimei Yang, Jie Su

CytoJournal, Journal Year: 2024, Volume and Issue: 21, P. 73 - 73

Published: Dec. 26, 2024

Septic cardiomyopathy (SCM), as a complication of the septic process, severely affects myocardial function patients, but its pathogenesis remains unclear. The article aims to explore mechanism tripartite motif 10 (TRIM10) in rats with SCM and provide animal experimental basis for treatment prevention SCM. An rat model was constructed by intraperitoneal injection lipopolysaccharide (LPS). Sh-NC sh-TRIM10 groups were injected sh-NC tail vein 3 consecutive days before modeling. expression TRIM10 detected Western blot reverse transcription-polymerase chain reaction analyses. Hematoxylin-eosin staining performed observe pathological changes myocardium. Cardiomyocyte apoptosis flow cytometry. Serum levels cardiac troponin I, myohemoglobin, creatine kinase-MB, interleukin-18 (IL-18), interleukin-1 β (IL-1β), tumor necrosis factor-α (TNF-α), superoxide dismutase, glutathione peroxidase (GSH-Px) enzyme-linked immunosorbent assay. Apoptosis-related proteins toll-like receptor 4 (TLR4)/nuclear transcription factor-κB (NF-κB) pathway-related explored increased LPS group (P < 0.0001). Myocardial tissue injury improved after reduction compared that group. Knockdown decreased MDA 0.01), IL-18 0.0001), IL-1β TNF-α 0.0001) contents SOD 0.001) GSH-Px those reduced H9C2 cells After interference, p-P65/P65 TLR4 decreased. knockdown can reduce inflammation, oxidative stress, has protective effect on cardiomyocytes, which may be attributed regulation TLR4/NF-κB pathway.

Language: Английский

Dexmedetomidine improves clinical outcomes in sepsis-induced myocardial injury: a retrospective cohort study DOI Creative Commons
Yuan Liu, J. Ouyang, Cuicui Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 15, 2025

The efficacy of dexmedetomidine (DEX) in treating sepsis-induced myocardial injury (SIMI) remains unclear. In this study, we explored the relationship between DEX use and clinical outcomes patients with SIMI, focusing on dosage treatment duration. retrospective cohort analysis, identified SIMI from Medical Information Mart for Intensive Care IV (MIMIC-IV) database categorized them into non-DEX groups based intensive care unit treatment. baseline bias was reduced through propensity score matching (PSM). primary outcome 28-day mortality, whereas secondary were in-hospital mortality rates at 7 days, 90 1 year. association assessed using Kaplan-Meier analysis Cox proportional hazards models. After PSM, 373 group matched 579 to achieve a balanced distribution covariates. regression model demonstrated significant reduction associated use, yielding hazard ratio (HR) 0.61 (95% confidence interval [CI]: 0.47-0.78, P < 0.001). In-hospital also significantly decreased (HR = 0.43, 95% CI: 0.33-0.57, Lower observed doses >0.4 μg/kg/h, particularly range 0.400-0.612 total >3.113 mg during hospitalization, durations exceeding 72 h improved risk all intervals. Regarding 28 our subgroup analyses indicated interaction Sequential Organ Failure Assessment invasive mechanical ventilation. administration year SIMI. These findings require validation future studies.

Language: Английский

Citations

0
p16INK4a Aggravated Sepsis-associated Cardiac Injury by Inhibiting the PI3K/AKT Pathway and Inducing Redox Imbalance DOI
Baihong Li, Wei Wang, Xiaoyan Wang

et al.

Journal of Cardiovascular Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 14, 2025

Language: Английский

Citations

0
Integrated Omics Insights into Dapagliflozin Effects in Sepsis-Induced Cardiomyopathy DOI Creative Commons

Weiwei Lai,

Li Liu, Shuhang Wang

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 286 - 286

Published: Feb. 14, 2025

Sepsis-induced cardiomyopathy (SIC) is a life-threatening cardiac complication of sepsis with limited therapeutic options. Dapagliflozin, sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated cardioprotective effects in heart failure, but its role mitigating sepsis-related dysfunction remains unclear. A retrospective cohort analysis was conducted to assess the impact pre-hospital dapagliflozin use on major adverse cardiovascular events (MACEs) and survival patients SIC. Additionally, murine SIC model established using cecal ligation puncture (CLP) evaluate function, histopathology, biomarkers myocardial injury. Transcriptomic metabolomic profiling, combined multi-omics integration, employed elucidate molecular mechanisms underlying dapagliflozin's effects. In clinical cohort, associated significant reduction risk MACE improved outcomes. model, restored reduced injury, alleviated histological damage. Multi-omics revealed that modulates inflammatory responses, enhances autophagy, regulates metabolic pathways such as AMPK signaling lipid metabolism. Key regulatory genes metabolites were identified, providing mechanistic insights into actions dapagliflozin. Dapagliflozin significantly improves outcomes sepsis-induced through multi-level regulation inflammation, energy metabolism, cellular pathways. These findings establish promising strategy for SIC, offering translational treatment dysfunction.

Language: Английский

Citations

0
Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism DOI Creative Commons

Xueting Yu,

Jie Gao, Chunxiang Zhang

et al.

Intensive Care Medicine Experimental, Journal Year: 2025, Volume and Issue: 13(1)

Published: Feb. 18, 2025

Abstract Sepsis is a life-threatening multi-organ dysfunction syndrome caused by dysregulated host response to infection, posing significant global healthcare challenge. Sepsis-induced myocardial (SIMD) common complication of sepsis, significantly increasing mortality due its high energy demands and low compensatory reserves. The substantial mitochondrial damage rather than cell apoptosis in SIMD suggests disrupted cardiac metabolism as crucial pathophysiological mechanism. Therefore, we systematically reviewed the mechanisms underlying SIMD, including alterations substrates, excitation–contraction coupling processes, dysfunction, autophagy biogenesis, summarizing potential therapeutic targets within them.

Language: Английский

Citations

0
Monotropein inhibits MMP9-mediated cardiac oxidative stress, inflammation, matrix degradation and apoptosis in a mouse and cell line models of septic cardiac injury DOI

Wanqi Wu,

Jun Wang, Guanglu Wang

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: March 20, 2025

Language: Английский

Citations

0
Exploring the pathogenesis of sepsis-induced cardiomyopathy: Multilayered mechanisms and clinical responses DOI Creative Commons
Jinfang Xue,

Ning Zhou,

Quan Li

et al.

Science Progress, Journal Year: 2025, Volume and Issue: 108(1)

Published: Jan. 1, 2025

Sepsis-induced cardiomyopathy (SIC), as a common complication in the intensive care unit, not only increases complexity of patient but also greatly enhances risk death. Currently, clinical management SIC remains challenging, mainly due to its pathogenesis and lack targeted therapies. Although specific etiology is yet fully understood, existing studies have revealed several vital pathological processes that are intertwined contribute progression disease. This narrative review summarizes SIC, which involves multiple aspects including inflammatory response, mitochondrial dysfunction, cell death mechanisms, immune regulation, calcium homeostasis imbalance. Given multifactorial future need explore interactions between these mechanisms how intervene develop more precise effective therapeutic strategies reduce mortality improve prognosis patients with SIC.

Language: Английский

Citations

0
Integrated Metabolomics and Network Pharmacology Reveal the Mechanisms of Xuebijing in Counteracting Sepsis-induced Myocardial Dysfunction DOI

Yan Hu,

Yang Xu, Jian Gao

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 119729 - 119729

Published: April 1, 2025

Language: Английский

Citations

0
Interaction between post-tumor inflammation and vascular smooth muscle cell dysfunction in sepsis-induced cardiomyopathy DOI Creative Commons
Rui Liu, Lina Jia, Yu Lin

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 10, 2025

Sepsis-induced cardiomyopathy (SIC) presents a critical complication in cancer patients, contributing notably to heart failure and elevated mortality rates. While its clinical relevance is well-documented, the intricate molecular mechanisms that link sepsis, tumor-driven inflammation, cardiac dysfunction remain inadequately explored. This study aims elucidate interaction between post-tumor intratumor heterogeneity, of VSMC SIC, as well evaluate therapeutic potential exercise training specific pharmacological interventions. Transcriptomic data from NCBI GEO databases were analyzed identify differentially expressed genes (DEGs) associated with SIC. Weighted gene co-expression network analysis (WGCNA), ontology (GO), KEGG pathway enrichment analyses utilized biological significance these genes. Molecular docking dynamics simulations used investigate drug-target interactions, immune infiltration mutation carried out by means platforms like TIMER 2.0 DepMap comprehend influence DVL1 on responsiveness. Through utilization datasets, we discovered core exhibited remarkable up-regulated expression both SIC diverse kinds cancers, which poor prognosis inflammatory responses. revealed Digoxin could bind reduce oxidative stress The module related was identified WGCNA, demonstrated distinctive cell patterns impact immunotherapeutic resistance. regulator other cancers and, therefore, can serve target. present suggests targeted therapies enhance response regimens may be novel tool during particularly patients. drugs, Digoxin, require further vivo studies confirm their effects efforts improve outcomes immunotherapy-resistant

Language: Английский

Citations

0
Ablation of Mitophagy Receptor FUNDC1 Accentuates Septic Cardiomyopathy through ACSL4-Dependent Regulation of Ferroptosis and Mitochondrial Integrity DOI
Fengjuan Li,

Huantao Hu,

Liangyan Wu

et al.

Free Radical Biology and Medicine, Journal Year: 2024, Volume and Issue: 225, P. 75 - 86

Published: Sept. 24, 2024

Language: Английский

Citations

3
Clinical effects of dexmedetomidine on patients with sepsis and myocardial injury DOI Creative Commons
Xiaomin Si,

Zhonglue Huang,

Zeping Pan

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(43), P. e40257 - e40257

Published: Oct. 25, 2024

This study aimed to explore the organ-protective effects of dexmedetomidine in patients with sepsis combined myocardial injury. From December 2021 2023, 263 injury were included based on inclusion and exclusion criteria. They divided into an experimental group (n = 122), who had previously received dexmedetomidine, a control 141), midazolam. After matching baseline characteristics, treatment outcomes between 2 groups compared. In propensity score-matched cohort patients, each 62 individuals balanced characteristics. The showed significantly lower heart rates days 1, 3, 7 compared ( P < .05). Biomarkers high-sensitivity troponin I creatine kinase-MB decreased by 3 7, levels group. B-type natriuretic peptide also 7. Heart function improved both groups, showing better outcomes. Inflammatory markers after days, having levels. Hospitalization duration was similar groups. Dexmedetomidine reduces rate inflammatory markers, protects cells, improves cardiac It shows potential as option, future research needed assess its long-term efficacy safety.

Language: Английский

Citations

2